openPR Logo
Press release

Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC

Huateng Pharma Supplies Intermeidates of Pemetrexed Against

Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical for the survival of cancer cells, thereby inhibiting tumor growth.

In February 2004, the U.S. Food and Drug Administration (FDA) approved pemetrexed disodium in combination with cisplatin to treat a rare cancer, malignant pleural mesothelioma. Malignant pleural mesothelioma is a rare lung pleural cancer. Pemetrexed disodium can interfere with cancer cell replication and further promote tumor cell apoptosis by blocking the unique mechanism of 3 key enzymes of cancer cell metabolism.

This treatment plan is a synergistic inhibitory effect of three targets, which is superior to the single-target treatment plan using cisplatin in the past. At the same time, by supplementing folic acid and vitamins, the toxic and side effects can be effectively controlled and the patient's tolerance can be enhanced. In August 2004, the FDA approved pemetrexed disodium as a second-line treatment for locally advanced lung cancer or metastatic non-small cell lung cancer with fast approval. In December 2005, pemetrexed disodium, a patented drug of Eli Lilly, was launched in China and was approved for the treatment of malignant pleural mesothelioma.

According to the statistics of the world's best-selling drugs, the sales of pemetrexed in 2005 were 463 million US dollars, and in 2014 it reached a peak of 2.792 billion US dollars. Sales in 2017 were $2.063 billion. Its global sales declined after 2015 due to patent expiry.

In December 2005, Eli Lilly's pemetrexed disodium was launched in China. With the addition of domestic imitation products, the market competition was fierce.

In the first three quarters of 2021, domestic sales of pemetrexed disodium reached 3.679 billion, a year-on-year increase of 4.19%. The drug sales market is crowded by generic drug companies, accounting for 78.49%. However, affected by volume purchases, only original research drugs and products that have passed the consistency evaluation of generic drugs can enter the centralized procurement process. Therefore, Sichuan Huiyu Pharma and Eli Lilly are more competitive than other companies, accounting for 42.55% and 21.51% respectively.

Huateng Pharma, as a leading pharmaceutical intermediates supplier in China, can provide CAS NO.137281-39-1, CAS NO.165049-28-5, CAS NO.1118-89-4, CAS NO.155405-80-4 and CAS NO.3140-73-6 from lab to commercial scale, which can be used as Pemetrexed disodium intermediates. Also, we can provide CDMO services to meet your requirements, combining a high level of competencies, equipment and quality.

Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China
Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China
Email: sales@huatengusa.com
Website: https://us.huatengsci.com/
Zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818

Huateng Pharma is a global provider in contract development and manufacturing for intermediates.  With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC here

News-ID: 2662737 • Views: 277

More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. The U.S. Food and Drug Administration (FDA) approved it for flea treatment in dogs under the trade name Bravecto in May 2014 and for topical treatment in cats in November 2019. Fluralaner is a novel isooxazoline broad-spectrum insecticide that acts on γ-aminobutyric acid (GABA) receptors and has good activity against ticks, fleas,
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system disease in the world Tumors cannot be cured by traditional chemotherapy regimens. Bortezomib is the
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number
The Future of Treatment For Type 2 Diabetes
Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research. Previously, The Lancet Diabetes Endocrinology published an in-depth review detailing novel therapeutic targets for T2DM, mechanisms of drug action, and corresponding hypoglycemic efficacy. It involves innovation

All 5 Releases


More Releases for Pemetrexed

Pemetrexed Market Development Trends & Competitive Analysis by Leading Industry …
Allied Market Research added new research on Pemetrexed Market: Global Opportunity Analysis and Industry Forecast, 2022-2029. The Pemetrexed Market explores comprehensive study on various segments like size, share, development, innovation, sales and overall growth of major players. The research is based on primary and secondary data sources and it consists both qualitative and quantitative detailing. Request The Free Sample PDF Of This Report: https://www.alliedmarketresearch.com/request-sample/10728 Which market perspectives are enlightened in the Pemetrexed Market report? Executive
Pemetrexed Disodium API Market Size, Share, Development by 2025
LP INFORMATION recently released a research report on the Pemetrexed Disodium API market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Pemetrexed Disodium APImarket by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of Pemetrexed Disodium APImarket, market definition, overview, industry opportunities
Pemetrexed Market | Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmace …
The Pemetrexed market demand is anticipated to flourish during the forecast period 2020-2027. The report offers information related to import and export, along with the current business chain in the market at the global level. This report provides an in-depth overview of the Pemetrexed market. This includes market characteristics, consisting of segmentation, market share, trends and strategies for this market. The Market Size section provides historical forecasts of market growth
Pemetrexed Disodium API Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Pemetrexed Disodium API Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Pemetrexed Disodium API players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Pemetrexed Disodium API with respect
Pemetrexed Market is expected to grow at the considerable growth rate, due to in …
The Latest Study Report On Pemetrexed Market Pemetrexed disodium is a chemotherapy drug used in the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC). The generic version of the drug is named as pemetrexed. Currently, it is available in powder form, which is then converted to solution for intravenous infusion. Get access to report sample @ https://straitsresearch.com/report/Pemetrexed-Market/request-sample According to the Cancer Research UK, lung cancer is the third most prevalent
Pemetrexed Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Pemetrexed Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 102 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/global-pemetrexed-market_p106979.html   Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured